In vitro study details the increased performance and potential of CPSI’s Supercritical Nitrogen cryoablation device for the epicardial based ablation of cardiac tissue

OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the enhanced performance CPSI’s next generation supercritical nitrogen (SCN) cryoablation device and its potential application in the treatment of cardiac arrhythmias. The study, titled “Evaluation of a New Epicardial Cryoablation System for the Treatment of Cardiac Tachyarrhythmias”, published as an open access article in the journal Trends in Medicine (February 2, 2018, accessible free of charge at: http://www.oatext.com/evaluation-of-a-new-epicardial-cryoablation-system-for-the-treatment-of-cardiac-tachyarrhythmias.php), was a multi-institutional collaboration between researchers from CPSI and Binghamton University.

The article details developments in CPSI’s cardiac cryoablation technology platform. The study investigated the performance of the patented Supercritical Nitrogen (SCN) cryoablation system and epicardial cryoablation probe developed by CPSI. The studies, conducted using a series of heat loaded engineering and tissue models, demonstrated the ability of the system to quickly and effectively deliver an ablative dose. Commenting on the study, Dr. John M. Baust (CPSI President and Lead Scientist) stated “We have been working on a series of a next generation cryoablation devices and probes for targeting various cardiac arrhythmias for a number of years. These activities have resulted in the development of a platform of new ablation probes and catheters, the ICEolate platform, designed to support ablation of cardiac tissue using either a epicardial or endocardial approach. This specific study focused on evaluations of the epicardial cryoprobe technology. The results demonstrate that the SCN system is able to generate ablative power several fold greater than today’s commercial cryoablation systems and as such deliver a ablative dose in less than one minute in many cases.”

This study was conducted as part of CPSI’s ongoing research and technology development program which involves the development of a next generation cryoablation devices and approaches for the treatment of various disease states. Ongoing efforts continue to build upon this success and are focusing on continued development, optimization and testing of these new devices. Speaking to the broader device development program at CPSI, Baust added “while this study focused on our prototype epicardial cardiac probe, we are also actively developing linear and balloon tipped catheter technologies as part of the ICEolate platform to support endocardial based procedures. The power of the patented cryoablation engines that CPSI’s engineers have developed has opened a number of doors for advanced treatment for various diseases. We are excited to take the next steps with this technology.” With development underway, CPSI is poised to embark down the commercialization path. To this end, Baust commented “We are actively seeking investors and partners through a variety of mechanisms to join our team to bring this potentially lifesaving technology platform to the market.”

Click Here to read the full Press Release: New Cryoablation Device Targets Enhanced Treatment of Cardiac Arrhythmias 

View other CPSI Biotech news and recent patent announcements

In vitro study details how the gradual dose escalation of calcitriol, a hormonally active metabolite of vitamin D3, increases prostate cancer cell sensitivity to freezing injury and may provide an alternate combinatorial approach in the treatment of prostate cancer

OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the potential benefit of the combination of calcitriol pre-treatment and freezing (cryoablation) for targeting prostate cancer. The study, titled Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model, published in the open access journal Cancer Control January-March 2018 edition (http://journals.sagepub.com/doi/full/10.1177/1073274818757418) was a multi-institutional collaboration between researchers from CPSI and Binghamton University.

The article details the impact of exposing prostate cancer cells to a gradually increasing dose of calcitriol over a one month period and then exposing cells to mild sub-freezing temperatures associated with a cryoablative procedure. The study investigated the impact of the application of a gradual calcitriol dose escalation regime in comparison to a single (1 day) high dose exposure regime as well as freezing alone in an in vitro prostate cancer cell model. The data show that exposing cancer cells to calcitriol in combination with mild freezing resulted in increased cell death compared to either treatment alone. Further, the data demonstrated that gradual dose escalation of calcitriol yielded a similar outcome as acute high dose exposure. Commenting on the study, Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) stated “cryoablation is a very effective treatment modality used widely to treat various cancers. One limitation of Cryo is that different cancer cells (stages and types) have been shown to have differing tolerances to mild freezing temperatures associated with the outer edge of the frozen mass. In addition to developing advanced cryoablative devices, one of our foci at CPSI is to identify new combinatorial strategies to increase cancer destruction at these mild sub-freezing temperatures. This study demonstrates that the combination of calcitriol and freezing can yield prostate cancer destruction at temperatures as warm as -15°C, whereas typically temperatures of -40°C or colder are necessary for complete destruction.” Dr. Kimberly Santucci (CPSI Research Scientist and the study’s first author) stated “the anticancer properties of VD3 metabolites, including calcitriol, have been extensively studied and we previously reported on the benefits of the combination of calcitriol and freezing.  While beneficial, previous studies focused on the acute administration and short term exposure of high dose calcitriol.  Clinical translation of that approach would require multiple surgical procedures over several days.  The objective of this study was to model the gradual increase of calcitriol concentration such as might be obtained via a one month oral dosing regimen.  Our findings suggest that the application of gradual dose escalation results in similar sensitization of cancer cells to freezing as an acute high dose regime.”

Ongoing efforts at CPSI continue to build upon this success and are focusing on further development, optimization and testing of new minimally invasive surgical devices designed to treat cancers including prostate, pancreatic, bladder, kidney, esophageal and breast cancer among others. Speaking to the broader device development program at CPSI, Dr Baust noted “an ongoing Phase II SBIR award from NCI has provided CPSI the opportunity to ramp up our R&D studies around our advanced cryoablation device platform in combination with vitamin D3 metabolite pre-treatment for the treatment of liver and pancreatic cancers. This project incorporates several of CPSI’s patented technologies, including our cryoengines, thermal ablation probes and catheters and adjunctive anticancer agents (SensitICERs). With success, these efforts will provide an advanced minimally invasive approach for treating various cancers.” With development underway, CPSI is poised to embark down the commercialization path. To this end, Baust commented “We are actively seeking investors and partners through a variety of mechanisms to join our team to bring this potentially lifesaving technology platform to the market.”

More information on the CPSI’s cryoablation and SensitICER technologies can be found on CPSI’s website at www.CPSIBiotech.com/technologies. The full press release can be accessed here.

In Vitro Study Shows Combinatorial Ablative Strategies Yield Improved Destruction of Pancreatic Cancer Cells

OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the potential benefit of the combination of heat (hyperthermia) and freezing (cryoablation) based ablation strategies for the targeting of pancreatic cancer. The study, titled Dual Thermal Ablation of Pancreatic Cancer Cells as an Improved Combinatorial Treatment Strategy, published as an open access article in the journal Liver and Pancreatic Sciences, was a multi-institutional collaboration between researchers from CPSI and Binghamton University.

The article details the impact of treating pancreatic cancer cells using two ablative strategies, cryo and hyperthermic ablation, used clinically to treat pancreatic as well as other cancers. One arm of the study investigated the impact of the combined application of these ablative treatments strategies on pancreatic cancer in an in vitro cell model. The data show that the combination of exposing cancer cells to heat based ablation followed by freezing results in increased cell death compared to when either is applied as a single exposure (mono) therapy. Commenting on the article, Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) stated “this study demonstrates that ablative therapies provide for an effective means of destroying pancreatic cancer cells. These initial findings from this in vitro suggest that further investigation into the use of a dual thermal ablation regime for treating pancreatic cancer is warranted.”

This study was conducted as part of CPSI’s ongoing research and technology development program focused on the development of a next generation cryoablation device (FrostBite™) and approach for the treatment of pancreatic cancer. The initial development efforts behind FrostBite™ and the DTA study have been supported, in part, by a Phase I and II SBIR grant awarded to CPSI by the National Cancer Institute. Ongoing efforts at CPSI continue to build upon this success and are focusing on further development, optimization and testing of FrostBite™ for the treatment of pancreatic cancer as well as other gastroenterological (GI) based cancers. With development underway, CPSI is poised to embark down the commercialization path. To this end, Dr. John M. Baust commented “We are actively seeking investors and partners to join our team to bring this potentially lifesaving technology platform to the market.” To enable this, a start-up company (GI Cryo, Inc.) has been formed focused in the GI area to commercialize FrostBite™ and other related technologies.

The open access article, initially published online November 30th , is timely in view of the recent increased interest in use of cryoablation for the treatment of cancer and can be accessed free of charge via the Liver and Pancreatic Science website at http://www.oatext.com/Dual-thermal-ablation-of-pancreatic-cancer-cells-as-an-improved-combinatorial-treatment-strategy.php#Article.

Click Here to read the full Press Release: Combinatorial Ablative Strategies Yield Improved Destruction of Pancreatic Cancer Cells

More information on FrostBite™ or any of CPSI’s other technologies is available on CPSI Biotech’s website www.cpsibiotech.com.

CPSI researchers present on the SmartThaw cell thawing system and RevitalICE reagent at ISBiotech Fall Conference

OWEGO, NY — CPSI Biotech president, Dr. John M. Baust (President and Lead Scientist), has been invited to presented at the 2017 ISBioTech 5th Annual Fall Meeting in Virginia Beach, VA (Dec 10-13). CPSI’s podium presentation will detail recent studies focused on improving the thawing process and quality of frozen cell and tissue products using CPSI’s SmartThaw™ device and RevitalICE™ reagent.

Dr. Baust’s presentation will feature studies conducted by CPSI researchers on human hematopoietic and mesenchymal stem cells. Commenting on the research, Dr. Baust stated “our continuing studies demonstrated that sample quality and processing can be improved using SmartThaw™ and RevitalICE™. SmartThaw™ provides improved processing of frozen products while in many cases also improving viability post-thaw. The RevitalICE™ post-thaw recovery reagent is designed to give researchers the ability to salvage samples which have been cryopreserved using dated approaches.”

SmartThaw is targeted for commercial launch in 2018.

Click Here to read the full Press Release: PR20171211_SmartThaw_ISBioTechFallConf

More information on SmartThaw™, RevitalICE™ or any of CPSI’s other technologies is available on CPSI Biotech’s website www.cpsibiotech.com.

More information on the International Society for Bioprocess Technology and the ISBioTech conference series can be found at www.isbiotech.org.

CPSI Biotech receives multi-year Phase II grant from the National Cancer Institute to develop FrostBite™ Cryoablation Technology for the Treatment of Pancreatic Cancer

Owego, NY – CPSI Biotech (CPSI) announced today it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).  The 2 year $1.7 million Phase II project focuses on the development of a next generation cryoablation device (FrostBite™) and approach for the treatment of pancreatic cancer.

Dr. John Baust (CPSI President) commented “the overall objective of FrostBite™ is to provide a powerful ablative tool to attack pancreatic cancer, which ultimately may reduce our reliance on other traditional approaches such as chemotherapy, radiation or major surgery to treat this deadly disease.”  The potential impact of the technology is tremendous.  Speaking about the technology, Dr. P. Jay Pasricha (Professor of Medicine and Neurosciences, Division of Gastroenterology, John Hopkins School of Medicine and consultant for CPSI) commented “We are very encouraged by the potential of  FrostBite™ EUS-cryocatheter platform.  The ability to target and freeze tissues in situ under endoscopic ultrasound guidance will provide for a more precise and minimally invasive strategy to treat cancer including pancreatic, esophageal and other tumors. We are looking forward to continuing our work with CPSI to bring this technology to the clinic.”

CPSI has been actively working on the development of the FrostBite™ cryocatheter for several years.  FrostBite™ is designed to be used in conjunction with CPSI’s patented cryoengine technologies to freeze (cryoablate) cancer in situ (in place within the body), thereby destroying a tumor. This new device and approach is designed to support the growing field of natural orifice transluminal endoscopic surgery (NOTES) in which “scarless” abdominal operations can be performed with an endoscope passed through the mouth thereby enabling the introduction of surgical tools, such as CPSI’s cryoprobe, into the stomach to target various tissues via the stomach wall avoiding the need for invasive external surgical procedures. In this manner, FrostBite™ is designed to be introduced to the stomach via an endoscopic ultrasound (EUS) device and then the cryoneedle tip of the catheter passes directly through the stomach wall into a tumor in the pancreas. The use of EUS allows for the real-time visualization of the tumor and positioning of the cryoneedle prior to cryoablative treatment.

The initial development efforts behind FrostBite™ were supported, in part, by a Phase I SBIR grant awarded to CPSI by NCI in 2015.  Phase I studies demonstrated proof of concept of this new technology and treatment paradigm and yielded the development of several prototype cryocatheters.  As part of Phase I development efforts, CPSI, in conjunction with collaborators at Johns Hopkins Medical, conducted a series of studies demonstrating the successful delivery of an ultra-cold (<-170°C), highly effective lethal insult (ablative dose) within a matter of minutes.  Phase 1 studies also involved collaborative efforts with researchers from the Institute of Biomedical Technology at Binghamton University.  Successful completion of Phase I studies enabled CPSI to pursue Phase II funding.  Phase II will build upon this success and focus on further development, optimization and testing of FrostBite™ for the treatment of pancreatic cancer as well as other gastroenterological (GI) based cancers.  Speaking to the Phase II, Dr. Baust noted “this is a great opportunity to continue the development of the FrostBite™ platform for the GI-based treatment of various cancers.  This Phase II will allow for continued engineering and testing of the next generation FrostBite™ cryocatheter. This project incorporates several of CPSI’s patented technologies, including our cryoengines, dual thermal ablation and adjunctive agents (SensitICERs).  With success, FrostBite™ will provide an advanced minimally invasive approach for treating pancreatic and other cancers.”  With Phase II development initiated, CPSI is poised to embark down the commercialization path. To enable this, a start-up company (GI Cryo, Inc.) has been formed focused in the GI area to commercialize FrostBite™ and other related technologies.  To this end, Baust commented “We are actively seeking investors and partners to join our team to bring this potentially lifesaving technology platform to the market.”

Click Here to read the Full Press Release on 24-7PressRelease

CPSI researchers present at the Cell Culture and Cell Therapy Bioprocessing conference

OWEGO, NY — CPSI Biotech president, Dr. John M. Baust (President and Lead Scientist), presented today at the Cell Culture and Cell Therapy Bioprocessing conference in Philadelphia, PA (June 26-27). CPSI’s podium presentation detailed recent studies focused on improving the thawing process and quality of frozen cell and tissue products using CPSI’s SmartThaw™ device and RevitalICE™ reagent.

Dr. Baust’s presentation featured studies conducted by CPSI researchers on human hematopoietic and mesenchymal stem cells. Commenting on the research, Dr. Baust stated “this study demonstrated that sample quality and processing can be improved using SmartThaw™ and RevitalICE™. SmartThaw™ provides improved processing of frozen products while in many cases also improving viability post-thaw. Further, the RevitalICE™ post-thaw recovery reagent was shown to give researchers the ability to salvage samples which have been cryopreserved using dated approaches.”

Providing further insight, Dr. Kristi Snyder (Director of Operations and Principal Scientist) stated “SmartThaw™ provides a viable alternative to water baths offering a clean, dry and documentable process while delivering improved cell recovery.” When asked about RevitalICE™, Dr. Snyder stated “RevitalICE™ is the newest member of the SmartBio platform. RevitalICE™ is a molecular based cell culture media additive designed to modulate a cell’s recovery response. RevitalICE™ can be used with any sample which is currently frozen, using any type of preservation media, to more effectively recover samples following thawing, thereby improving sample quality and function.”
Dr. Baust continued “RevitalICE™ is designed to minimize alterations in cell function thereby improving cryopreservation outcome without front end process changes. This technology offers potential benefit for the billions of samples currently cryopreserved globally today.”

Development activities involving SmartThaw™ and RevitalICE™ are ongoing. “We are very excited to take the next steps towards commercialization for both of these technologies. SmartThaw™ will provide a vital link in improving cryopreserved cell handling. We have placed a number of pre-production units with select collaborators to gain end-user feedback to help finalize the product for commercialization. This has been a long process but the information we are collecting on SmartThaw™ has been invaluable. RevitalICE™ remains in the R&D stage, however, reception of the initial data has been very positive” stated Snyder. Currently, CPSI is targeting commercial launch of SmartThaw™ in 2018 with RevitalICE™ following thereafter.

Dr. John M. Baust Presents at ISBiotech 2017

OWEGO, NY — CPSI Biotech’s CEO and Lead Scientist gave a podium presentation Monday morning at the 2017 ISBiotech 7th Annual Spring Meeting in Washington, DC (March 6-8). The presentation titled “New Technologies for Improved Handling of Cryopreserved Samples”, given by Dr. John M. Baust, focused on the recent research and development activities relating to CPSI’s SmartThaw™ dry thawing device and RevitalICE cell culture reagent.

As part of the presentation, Dr. Baust focused on educating and reviewing attendees’ current cryopreservation practices and the challenges associated with many of protocols, as well as discussing new technologies and development efforts in the area of modulating the cellular-molecular response to cryopreservation as a path to improve cell recovery and function. Dr. Baust also presented data recently collected by CPSI scientists related to thawing of samples cryopreserved in 5 ml cryovials using SmartThaw™, a next generation device developed by CPSI Biotech for controlled and rapid dry thawing.

SmartThaw is targeted for commercial launch in 2017.

Click Here to read the full Press Release: CPSI Scientists Present at ISBiotech 2017_PR20170308

View other CPSI Biotech news and recent patent announcements

US Patent issued for new multi-functional thermal ablation device developed by CPSI Biotech

OWEGO, NY — CPSI Biotech is proud to announce the issuance of a patent (US Pat#: 9,566,105) by the United States Patent and Trademark Office covering device design and method of use of a new multi-functional thermal ablation technology to be used for the treatment of diseases ranging from cancer or heart disease.

This multi-functional thermal ablation technology offers the ability to apply both heat and cryogenic energy to tissue using a single device, enabling controlled, real-time application of a dual thermal ablation strategy. The dual thermal ablation system enables the delivery of a multitude of therapeutic treatment options, including heat and cold, along with anti-cancer agents, alone or in any combination as desired. Dr. John M. Baust, President and CEO of CPSI Biotech, stated “This technological platform will offer a physician the ability to apply both heat and cryotherapy in conjunction or alone, all from a single probe to ablate targeted tissue. The ability to deliver multiple ablative energy insults in a single device will eliminate the need for multiple systems and probe switching during a procedure, thereby reducing patient risk, procedure time and overall cost.”

Regarding CPSI Biotech’s future plans for the technology, Baust stated, “We continue to work on the development of this innovative technology. Our goal is to move through the R&D phase and into pilot studies with a clinical collaborator with this technology over the next year.”

Click Here to read the full Press Release: US Patent issued for new multi-functional thermal ablation device

View other CPSI Biotech news and recent patent announcements

Presentations at CRYO2016 Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Studies focused on the FrostBite device platform and cancer response to cryoablation highlight the potential use of this next generation technology for the treatment of pancreatic and esophageal cancer.

August 3, 2016 – Owego, NY – The need for the development of new devices and strategies to treat cancer was front and center at this year’s annual meeting of the Society for Cryobiology held in Ottawa, Canada in the session “Cool Developments in Cryomedicine”. This 2 part, 4-hour session featured 9 presentations focused on new developments in the use of cryo for disease treatment. As part of the session, CPSI scientists presented three studies focusing on molecular studies and device development in the areas of prostate (John M. Baust, Ph.D., CPSI President), pancreatic (Anthony Robilotto, MS., CPSI Engineer) and esophageal cancer (Kristi Snyder, Ph.D., Principal Scientist). Central to these studies was the incorporation of several of CPSI’s new device technologies including the PSN cryoablation device, FrostBite cryoablation catheter and EsoAblate cryoprobe. The FrostBite and EsoAblate cryoprobes are under development for the minimally invasive endoscopic based treatment of pancreatic and esophageal cancer, among other gastrointestinal cancers. The studies included discussion of cancer cell response to freezing, device design and characterization analysis as well as data from a series of studies conducted using tissue engineered pancreas and esophageal cancer models. The presentations also included results from preliminary in vivo studies conducted in conjunction with collaborators at Johns Hopkins Medical which demonstrated the successful translation of CPSI’s engineering and life science development into functional systems capable of delivering of an ultra-cold, highly lethal insult (ablative dose) within a matter of minutes.

Click here to read the full press release: Presentations Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Contact us to learn more about CPSI’s Cryoablation Medical Device Research & Development Programs

View other CPSI Biotech news and recent patent announcements